RS59599B1 - Formulacije tableta neratinib maleata - Google Patents
Formulacije tableta neratinib maleataInfo
- Publication number
- RS59599B1 RS59599B1 RS20191417A RSP20191417A RS59599B1 RS 59599 B1 RS59599 B1 RS 59599B1 RS 20191417 A RS20191417 A RS 20191417A RS P20191417 A RSP20191417 A RS P20191417A RS 59599 B1 RS59599 B1 RS 59599B1
- Authority
- RS
- Serbia
- Prior art keywords
- tablet formulations
- neratinib maleate
- neratinib
- maleate
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25940309P | 2009-11-09 | 2009-11-09 | |
EP10779339.0A EP2498756B2 (en) | 2009-11-09 | 2010-11-02 | Tablet formulations of neratinib maleate |
PCT/IB2010/054964 WO2011055303A1 (en) | 2009-11-09 | 2010-11-02 | Tablet formulations of neratinib maleate |
Publications (2)
Publication Number | Publication Date |
---|---|
RS59599B1 true RS59599B1 (sr) | 2020-01-31 |
RS59599B2 RS59599B2 (sr) | 2023-03-31 |
Family
ID=43478191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20191417A RS59599B2 (sr) | 2009-11-09 | 2010-11-02 | Formulacije tableta neratinib maleata |
Country Status (21)
Country | Link |
---|---|
US (2) | US8518446B2 (sr) |
EP (3) | EP4066821A1 (sr) |
JP (3) | JP5835883B2 (sr) |
CN (2) | CN103893140B (sr) |
AR (2) | AR078952A1 (sr) |
AU (1) | AU2010316683B2 (sr) |
CA (1) | CA2780428C (sr) |
CY (1) | CY1122330T1 (sr) |
DK (1) | DK2498756T4 (sr) |
ES (1) | ES2757882T5 (sr) |
FI (1) | FI2498756T4 (sr) |
HR (1) | HRP20192026T4 (sr) |
HU (1) | HUE046606T2 (sr) |
LT (1) | LT2498756T (sr) |
NZ (1) | NZ599763A (sr) |
PL (1) | PL2498756T5 (sr) |
PT (1) | PT2498756T (sr) |
RS (1) | RS59599B2 (sr) |
SI (1) | SI2498756T2 (sr) |
TW (1) | TWI466690B (sr) |
WO (1) | WO2011055303A1 (sr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
CN101155579B (zh) | 2005-02-03 | 2012-10-31 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
CN103110948A (zh) | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
KR20130088908A (ko) | 2008-06-17 | 2013-08-08 | 와이어쓰 엘엘씨 | Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
CN109464445A (zh) | 2008-08-04 | 2019-03-15 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
ES2941894T3 (es) | 2009-04-06 | 2023-05-26 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib contra el cáncer de mama |
CA2780332C (en) | 2009-11-09 | 2018-01-30 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
PT2498756T (pt) * | 2009-11-09 | 2019-11-26 | Wyeth Llc | Formulações de comprimidos de maleato de neratinib |
WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
ES2963218T3 (es) | 2011-12-28 | 2024-03-25 | Global Blood Therapeutics Inc | Productos intermedios para obtener compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular |
US20160083343A1 (en) | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
CN111454200A (zh) | 2013-03-15 | 2020-07-28 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9818967B2 (en) * | 2013-06-28 | 2017-11-14 | Universal Display Corporation | Barrier covered microlens films |
CN104337782A (zh) * | 2013-08-02 | 2015-02-11 | 山东新时代药业有限公司 | 一种甲磺酸伊马替尼片剂 |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
WO2015112850A2 (en) * | 2014-01-23 | 2015-07-30 | Wenle Xia | Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders |
CA2916564C (en) | 2014-02-07 | 2023-02-28 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
ES2805008T3 (es) | 2014-02-17 | 2021-02-10 | Childrens Nat Medical Ct | Procedimiento y sistema para proporcionar recomendaciones para la ejecución óptima de procedimientos quirúrgicos |
JP6770946B2 (ja) * | 2014-07-25 | 2020-10-21 | ノバルティス アーゲー | 2−フルオロ−n−メチル−4−[7−(キノリン−6−イルメチル)イミダゾ[1,2−b][1,2,4]トリアジン−2−イル]ベンズアミドの錠剤 |
WO2017003951A1 (en) * | 2015-06-29 | 2017-01-05 | Phloronol, Inc. | Solid pharmaceutical compositions of brown algae |
SG10201912511WA (en) | 2015-12-04 | 2020-02-27 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
CN106831710A (zh) * | 2015-12-07 | 2017-06-13 | 常州爱诺新睿医药技术有限公司 | 一种无定型来那替尼或其药学上可接受的盐与药用辅料的固体分散体及其制备方法 |
CN106913529B (zh) * | 2015-12-24 | 2020-12-04 | 江苏恒瑞医药股份有限公司 | 一种来那替尼或其可药用盐药物组合物的制备方法 |
CA2937365C (en) * | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
CA3036053A1 (en) * | 2016-09-07 | 2018-03-15 | Celgene Corporation | Tablet compositions |
TWI778983B (zh) * | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
CA3060316A1 (en) * | 2017-04-28 | 2018-11-01 | Asana Biosciences, Llc | Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient |
CA3079916A1 (en) * | 2017-10-24 | 2019-05-02 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition containing quinoline derivative |
US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
CA3168680A1 (en) | 2020-01-31 | 2021-08-05 | Nanocopoeia, Llc | Amorphous nilotinib microparticles and uses thereof |
CA3181361A1 (en) * | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
US20220378788A1 (en) * | 2020-04-30 | 2022-12-01 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof |
WO2023172958A1 (en) * | 2022-03-08 | 2023-09-14 | Onkosxcel Therapeutics, Llc | Stable formulations of talabostat |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6384051B1 (en) | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
US7399865B2 (en) * | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
AR046544A1 (es) * | 2003-10-15 | 2005-12-14 | Wyeth Corp | Administracion oral de acido [2- (8,9 - dioxo - 2,6 - diazabiciclo [5.2.0] non -1 (7) - en - 2 - il ) alquil] fosfonico yderivados |
US20050142192A1 (en) | 2003-10-15 | 2005-06-30 | Wyeth | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
MX2007004489A (es) * | 2004-10-13 | 2007-09-21 | Wyeth Corp | Analogos de 17-hidroxiwortamina como inhibidores pi3k. |
WO2006085168A2 (en) * | 2005-01-07 | 2006-08-17 | Ranbaxy Laboratories Limited | Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide |
PT1896034E (pt) * | 2005-04-28 | 2010-05-06 | Wyeth Llc | Composições de tanaproget micronizado e métodos para a sua preparação |
EP1948180B1 (en) * | 2005-11-11 | 2013-03-13 | Boehringer Ingelheim International GmbH | Combination treatment of cancer comprising egfr/her2 inhibitors |
JP2007169273A (ja) * | 2005-11-28 | 2007-07-05 | Takeda Chem Ind Ltd | 杵付着を改善した医薬製剤 |
JP2007211005A (ja) * | 2006-01-16 | 2007-08-23 | Ono Pharmaceut Co Ltd | 固形製剤用組成物および固形製剤 |
TW200806282A (en) * | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
PE20081632A1 (es) * | 2007-01-12 | 2008-12-10 | Wyeth Corp | Composiciones de tableta en tableta |
US8697125B2 (en) * | 2007-02-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Tablet preparation without causing a tableting trouble |
JP2009089982A (ja) * | 2007-10-11 | 2009-04-30 | Ohara Yakuhin Kogyo Kk | 打錠用造粒物の造粒方法 |
WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
CN102470109A (zh) | 2009-07-02 | 2012-05-23 | 惠氏有限责任公司 | 3-氰基喹啉片剂制剂及其应用 |
PT2498756T (pt) * | 2009-11-09 | 2019-11-26 | Wyeth Llc | Formulações de comprimidos de maleato de neratinib |
-
2010
- 2010-11-02 PT PT107793390T patent/PT2498756T/pt unknown
- 2010-11-02 HR HRP20192026TT patent/HRP20192026T4/hr unknown
- 2010-11-02 EP EP22169771.7A patent/EP4066821A1/en active Pending
- 2010-11-02 HU HUE10779339A patent/HUE046606T2/hu unknown
- 2010-11-02 CA CA2780428A patent/CA2780428C/en active Active
- 2010-11-02 SI SI201031952T patent/SI2498756T2/sl unknown
- 2010-11-02 LT LT10779339T patent/LT2498756T/lt unknown
- 2010-11-02 ES ES10779339T patent/ES2757882T5/es active Active
- 2010-11-02 NZ NZ599763A patent/NZ599763A/en unknown
- 2010-11-02 RS RS20191417A patent/RS59599B2/sr unknown
- 2010-11-02 PL PL10779339.0T patent/PL2498756T5/pl unknown
- 2010-11-02 DK DK10779339.0T patent/DK2498756T4/da active
- 2010-11-02 FI FIEP10779339.0T patent/FI2498756T4/fi active
- 2010-11-02 CN CN201410082103.7A patent/CN103893140B/zh active Active
- 2010-11-02 EP EP10779339.0A patent/EP2498756B2/en active Active
- 2010-11-02 EP EP19154710.8A patent/EP3566697A1/en active Pending
- 2010-11-02 AU AU2010316683A patent/AU2010316683B2/en active Active
- 2010-11-02 WO PCT/IB2010/054964 patent/WO2011055303A1/en active Application Filing
- 2010-11-02 CN CN201080060546.6A patent/CN102724970B/zh active Active
- 2010-11-05 US US12/940,808 patent/US8518446B2/en active Active
- 2010-11-08 JP JP2010249385A patent/JP5835883B2/ja active Active
- 2010-11-08 TW TW99138396A patent/TWI466690B/zh active
- 2010-11-09 AR ARP100104156A patent/AR078952A1/es not_active Application Discontinuation
-
2013
- 2013-08-21 US US13/972,764 patent/US8790708B2/en active Active
-
2015
- 2015-02-06 JP JP2015021870A patent/JP2015091882A/ja not_active Withdrawn
-
2017
- 2017-02-06 JP JP2017019429A patent/JP2017075192A/ja not_active Withdrawn
-
2018
- 2018-11-14 AR ARP180103329A patent/AR114143A2/es not_active Application Discontinuation
-
2019
- 2019-11-14 CY CY20191101200T patent/CY1122330T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2498756T3 (pl) | Preparaty maleinianu neratynibu w postaci tabletki | |
HUS2000009I1 (hu) | Kétrétegû tabletta készítmények | |
HRP20181755T1 (hr) | Formulacije tableta s trenutnim oslobađanjem | |
LT3061445T (lt) | Labai koncentruotos farmacinės kompozicijos | |
HK1169960A1 (en) | Pharmaceutical formulation | |
IL215872A (en) | Indomethacin preparation | |
HK1198287A1 (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives 2--1- | |
HK1209649A1 (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives 2--1- | |
HK1201759A1 (en) | 4-methylpyrazole formulations 4- | |
EP2473168A4 (en) | PHARMACEUTICAL FORMULATIONS FOR INDIBULIN |